A Clinical Study on Yasmin® vs. Marvelon® in Chinese Women Requiring Contraception

Bayer

Status and phase: Completed; Phase 3

Conditions: Contraception

Treatments: Drug: Marvelon; Drug: Yasmin

Study type: Interventional

Funder types: Industry

Identifiers

NCT00185419

91330

308062

Details and patient eligibility

About

The purpose of this study is to evaluate the effectiveness in terms of prevention of pregnancy and safety of the oral contraceptive Yasmin and Marvelon on cycle control in healthy Chinese women

Full description

The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.

Bayer Schering Pharma AG, Germany is the sponsor of the trial.

Enrollment: 842 patients

Sex: Female

Ages: 20 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy Chinese female requesting contraceptives

Exclusion criteria

• Vascular, metabolic, hepatic, renal, oncologic and other diseases

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

842 participants in 2 patient groups

Arm 1

Active Comparator group

Treatment:

Drug: Yasmin

Arm 2

Active Comparator group

Treatment:

Drug: Marvelon